help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blethen, S. L.
Right arrow Articles by Johanson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blethen, S. L.
Right arrow Articles by Johanson, A.

Journal of Clinical Endocrinology & Metabolism, Vol 76, 574-579, Copyright © 1993 by Endocrine Society


ARTICLES

Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency

SL Blethen, P Compton, BM Lippe, RG Rosenfeld, GP August and A Johanson
Department of Pediatrics, State University of New York, Stony Brook 11794.

To identify factors influencing the response to GH therapy, we used a multiple regression model to analyze data from 632 naive prepubertal children with GH deficiency (GHD). There were 523 children with idiopathic and 109 children with organic GHD. They were treated with the same preparation of biosynthetic methionyl GH (somatrem, Protropin) for at least 1 yr. In children with idiopathic GHD, six variables predicted 40% of the response to treatment. They were (listed in relative importance, all P < 0.0001): age, log maximum GH, weight adjusted for height, dosing schedule, dose, and midparental height. Three variables, pretreatment growth rate, log maximum GH, and age, predicted 20% of the GH response in children with organic GHD. When data for all children were analyzed using analysis of covariance, children with idiopathic GHD grew better than those with organic GHD (mean +/- SD, 9.2 +/- 2.4 vs. 8.8 +/- 2.6 cm/yr; P < 0.0001). The children (both organic and idiopathic GHD) who did not respond well to treatment were younger and thinner than those who did. Early diagnosis and initiation of therapy should be beneficial to ultimate height attainment. The best response to GH therapy should be in young children with severe idiopathic GHD who receive daily weight-adjusted doses. The use of GH daily in higher doses would be expected to be most beneficial in older children with acquired and/or less severe GHD or in children who are underweight for height.


This article has been cited by other articles:


Home page
EndocrinologyHome page
Y. Wu, H. Sun, S. Yakar, and D. LeRoith
Elevated Levels of Insulin-Like Growth Factor (IGF)-I in Serum Rescue the Severe Growth Retardation of IGF-I Null Mice
Endocrinology, September 1, 2009; 150(9): 4395 - 4403.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. A. Romano, K. Dana, B. Bakker, D. A. Davis, J. J. Hunold, J. Jacobs, and B. Lippe
Growth Response, Near-Adult Height, and Patterns of Growth and Puberty in Patients with Noonan Syndrome Treated with Growth Hormone
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2338 - 2344.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Diller, E. J. Chow, J. G. Gurney, M. M. Hudson, N. S. Kadin-Lottick, T. I. Kawashima, W. M. Leisenring, L. R. Meacham, A. C. Mertens, D. A. Mulrooney, et al.
Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings
J. Clin. Oncol., May 10, 2009; 27(14): 2339 - 2355.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega
Prediction Model for Adult Height of Small for Gestational Age Children at the Start of Growth Hormone Treatment
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 477 - 483.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. D. Chernausek, P. F. Backeljauw, J. Frane, J. Kuntze, L. E. Underwood, and for the GH Insensitivity Syndrome Collaborative Gr
Long-Term Treatment with Recombinant Insulin-Like Growth Factor (IGF)-I in Children with Severe IGF-I Deficiency due to Growth Hormone Insensitivity
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 902 - 910.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. M. Brownstein, A. C. Mertens, P. A. Mitby, M. Stovall, J. Qin, G. Heller, L. L. Robison, and C. A. Sklar
Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4422 - 4427.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Donadieu, M.-A. Rolon, I. Pion, C. Thomas, F. Doz, M. Barkaoui, A. Robert, A. Deville, F. Mazingue, M. David, et al.
Incidence of Growth Hormone Deficiency in Pediatric-Onset Langerhans Cell Histiocytosis: Efficacy and Safety of Growth Hormone Treatment
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 604 - 609.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Coutant, S. Rouleau, F. Despert, N. Magontier, D. Loisel, and J.-M. Limal
Growth and Adult Height in GH-Treated Children with Nonacquired GH Deficiency and Idiopathic Short Stature: The Influence of Pituitary Magnetic Resonance Imaging Findings
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4649 - 4654.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. O. Reiter, K. M. Attie, T. Moshang Jr., B. L. Silverman, S. F. Kemp, R. B. Neuwirth, K. M. Ford, and P. Saenger
A Multicenter Study of the Efficacy and Safety of Sustained Release GH in the Treatment of Naive Pediatric Patients with GH Deficiency
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4700 - 4706.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet
Optimizing GH Therapy in Adults and Children
Endocr. Rev., August 1, 2001; 22(4): 425 - 450.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. B. Ranke, A. Lindberg, P. Chatelain, P. Wilton, W. Cutfield, K. Albertsson-Wikland, and D. A. Price
Prediction of Long-Term Response to Recombinant Human Growth Hormone in Turner Syndrome: Development and Validation of Mathematical Models
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4212 - 4218.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
The Essential Role of IGF-I: Lessons from the Long-Term Study and Treatment of Children and Adults with Laron Syndrome
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4397 - 4404.
[Abstract] [Full Text]


Home page
PediatricsHome page
G. M. Bright, J. R. Julius, J. Lima, and S. L. Blethen
Growth Hormone Stimulation Test Results as Predictors of Recombinant Human Growth Hormone Treatment Outcomes: Preliminary Analysis of the National Cooperative Growth Study Database
Pediatrics, October 1, 1999; 104(4): 1028 - 1031.
[Abstract] [Full Text]


Home page
PediatricsHome page
S. F. Kemp and J. P. Sy
Analysis of Bone Age Data From National Cooperative Growth Study Substudy VII
Pediatrics, October 1, 1999; 104(4): 1031 - 1036.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
G. M. Bright, J. D. Veldhuis, A. Iranmanesh, G. Baumann, H. Maheshwari, and J. Lima
Appraisal of Growth Hormone (GH) Secretion: Evaluation of a Composite Pharmacokinetic Model That Discriminates Multiple Components of GH Input
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3301 - 3308.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. L. Rosenbloom
A Mathematical Model for Predicting Growth Response to Growth Hormone Replacement Therapy--A Useful Clinical Tool or an Intellectual Exercise?
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1172 - 1173.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. B. Ranke, A. Lindberg, P. Chatelain, P. Wilton, W. Cutfield, K. Albertsson-Wikland, and D. A. Price
Derivation and Validation of a Mathematical Model for Predicting the Response to Exogenous Recombinant Human Growth Hormone (GH) in Prepubertal Children with Idiopathic GH Deficiency
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1174 - 1183.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Kriström, B. Carlsson, S. Rosberg, L. M. S. Carlsson, and K. Albertsson-Wikland
Short-Term Changes in Serum Leptin Levels Provide a Strong Metabolic Marker for the Growth Response to Growth Hormone Treatment in Children
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2735 - 2741.
[Abstract] [Full Text]


Home page
PediatricsHome page
J. K. Rao, J. R. Julius, T. J. Breen, and S. L. Blethen
Response to Growth Hormone in Attention Deficit Hyperactivity Disorder: Effects of Methylphenidate and Pemoline Therapy
Pediatrics, August 1, 1998; 102(2): 497 - 500.
[Abstract] [Full Text]


Home page
PediatricsHome page
G. P. August, J. R. Julius, and S. L. Blethen
Adult Height in Children With Growth Hormone Deficiency Who Are Treated With Biosynthetic Growth Hormone: The National Cooperative Growth Study Experience
Pediatrics, August 1, 1998; 102(2): 512 - 516.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Kristrom, C. Jansson, S. Rosberg, and K. Albertsson-Wikland
Growth Response to Growth Hormone (GH) Treatment Relates to Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Short Children with Various GH Secretion Capacities
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2889 - 2898.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. L. Blethen, J. Baptista, J. Kuntze, T. Foley, S. LaFranchi, and A. Johanson
Adult Height in Growth Hormone (GH)-Deficient Children Treated with Biosynthetic GH
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 418 - 420.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Rappaport, E. Mugnier, C. Limoni, H. Crosnier, P. Czernichow, J. Leger, J.-M. Limal, P. Rochiccioli, and S. Soskin
A 5-Year Prospective Study of Growth Hormone (GH)-Deficient Children Treated with GH before the Age of 3 Years
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 452 - 456.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society